Navigation Links
Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
Date:5/4/2009

POT-4 well tolerated by all subjects and sustained levels of drug reported after one treatment

LOUISVILLE, Ky., May 4 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it successfully completed its Phase I ASaP (Assessment of Safety of Intravitreal POT-4 Therapy for Patients with Neovascular Age-Related Macular Degeneration) clinical trial for the company's leading drug candidate, POT-4.

The ASaP trial was an open label, first-in-man, multi-center, single escalating dose study. The primary safety endpoint of this trial was achieved and the drug was well tolerated by all subjects at all doses tested, based on clinical signs, ophthalmic examinations, and laboratory results. No drug-related serious adverse events and no identifiable intraocular inflammation were reported. Additionally, significant sustained levels of POT-4 were consistently measured via serum analysis in subjects receiving the highest dose studied. The current POT-4 formulation is expected to provide sustained therapeutic ocular levels of the drug for several months following a single injection.

The data accumulated so far support the implementation of a comprehensive Phase II clinical program to further define the safety, efficacy and pharmacokinetic profile of POT-4 as a treatment for both dry and wet AMD.

"The safety and pharmacokinetic data strongly support the further development of POT-4 as a first-in-class treatment for patients with AMD," said Cedric Francois, President and CEO of Potentia Pharmaceuticals. "We believe that POT-4 has significant promise based on these early-stage findings and look forward to further testing of POT-4 in this disease, which is so prevalent and devastating to those affected by it."

About POT-4

POT-4 is a complement factor C3
'/>"/>

SOURCE Potentia Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
2. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
3. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
4. Study Shows Leconotide, an Investigative Calcium Channel Blocker, Has Potential as a Selective, Efficacious, Non-Opioid Pain Treatment
5. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
6. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
7. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
8. Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
9. Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkins Lymphoma
10. Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease
11. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014   Lincor Inc. today ... technology to New Jersey -based ... CarePoint Health will deploy Lincor,s PatientLINC technology across ... Hospital and Hoboken University Medical Center. ... software solutions to help hospitals reach new levels ...
(Date:8/19/2014)...  The Alabama Supreme Court, in a 6-3 decision on ... who mislead doctors into believing that prescription medicines the companies ... v. Wyeth, and the decision came after the Supreme Court ... year. Heninger Garrison Davis attorneys Lew Garrison and ... Danny Weeks . The decision won a ...
(Date:8/19/2014)... , Aug. 19, 2014 Talyst, a market ... exhibiting at the 2014 NPPA Summer Conference in ... be showcasing its 340B software products and services.   ... splitting solutions, supplying over 400 customers with a variety ... 340B solutions including its latest solution, AutoSplit® Contract Pharmacy ...
Breaking Medicine Technology:Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Talyst Exhibits at the NPPA Summer Conference 2
(Date:8/19/2014)... The National Cannabis Industry Association ... Symposium on Saturday, August 23, from 9:45am to ... Vegas. , Featuring keynotes by U.S. Representative Dina Titus ... the event will also include in-depth discussions on marijuana-infused ... doing federally to advance a legitimate and responsible cannabis ...
(Date:8/19/2014)... Plains, NY (PRWEB) August 19, 2014 ... they were named the winner of the 2014 ... Naturals took home the first place position in ... the marketplace specially-formatted eyeliner, which also includes a ... rich black color, plus lash-boosting technology. ...
(Date:8/19/2014)... 19, 2014 Just back from Glasgow where ... Booklets at the Commonwealth Games (July 23 – August ... kids stay off drugs. And the need for his work ... 850,000 people age16 to 59 consumed Class A drugs within ... abusing New Psychoactive Substances (NPS) drugs considered to be “legal ...
(Date:8/19/2014)... stay and could use this time as an opportunity to ... home. Now a study published in the August 20 ... the proportion of hospitalized smokers who successfully quit smoking after ... interactive voice response technology automated telephone calls to ... left the hospital. , "Most smokers want to ...
(Date:8/19/2014)... Program has selected three geriatric social work ... development and mentorship for projects that will improve ... for all older adults. , The 2014 Hartford/VA ... among veterans, transitions from VA nursing facilities back ... older veterans. The Hartford/VA Geriatric Scholars Program provides ...
Breaking Medicine News(10 mins):Health News:SATURDAY IN LAS VEGAS: U.S. Rep. Dina Titus, State Sen. Tick Segerblom Keynote National Cannabis Industry Association Southwest CannaBusiness Symposium 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3Health News:British Scientologist on a Mission to Save Youth from Drug Abuse 2Health News:Extended support helps patients stay smoke-free after hospital discharge 2
... The Kerlan Jobe Orthopaedic Clinic, a sports medicine clinic in ... million to settle allegations that it received illegal kickbacks from ... , The settlement resolves allegations that HealthSouth paid ... grants, donations to the Kerlan Jobe Foundation, loan forgiveness on ...
... , LOS ANGELES, Dec. 1 A decision issued ... Board (NLRB) has put at risk the guaranteed raises, healthcare ... professionals in Southern California. , "We have worked for years ... allow us to provide the professional care our patients need," ...
... tomography (CT) imaging of changes in tumors from colorectal ... have the potential to predict overall survival, according to ... JAMA . The addition of bevacizumab to ... survival in patients with stage IV colorectal cancer and ...
... , , ... (ASH) will host its annual High School Student Symposium at ... a.m. CST. The symposium, which encourages an interest in hematology, ... with the Society,s 51st Annual Meeting. This year, students will ...
... , MEXICO CITY, Dec. 1 ... will build a world-class center for biomedical and nanomedical ... research and development will be integrated with the National ... in the world. The research complex, scheduled to ...
... , BELLEVUE, Wash., Dec 1 Edifecs, ... Channel Modernization solutions announced an enhanced release of Edifecs ... migrations. XEngine Translator provides out-of-the-box 4010A1-5010 conversion maps, allows ... 4010A1 and 5010 in production, thus addressing most requirements ...
Cached Medicine News:Health News:Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations 2Health News:Labor Board Decision Puts Kaiser Workers' Pay, Healthcare, Pensions in Jeopardy 2Health News:Criteria based on CT imaging after chemotherapy may help predict survival 2Health News:ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 2Health News:ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum 3Health News:Mexico City to Build World-Class Hub for Medical Research 2Health News:Edifecs Delivers Enhanced HIPAA 4010A1 to 5010 Migration Capabilities for Healthcare Organizations 2Health News:Edifecs Delivers Enhanced HIPAA 4010A1 to 5010 Migration Capabilities for Healthcare Organizations 3
The ACMI TurboFlow 18 L and 10 L Insufflators provide rapid distention for all laparoscopic procedures. Eleven built-in safety features make insufflation reliable and dependable....
This multiple-function instrument allows the surgeon to grasp, coagulate, and transect tissue with a single instrument, eliminating the need for multiple instruments and, in some procedures, costly l...
Bipolar forceps...
... An in vitro Nucleic Acid ... using Microplate Chemiluminescence for the ... (HPV) Types 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and 68 ... Lowand High-Risk Groups in Cervical ...
Medicine Products: